Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa

AR de Mello Schier… - CNS & Neurological …, 2014 - ingentaconnect.com
Anxiety and depression are pathologies that affect human beings in many aspects of life,
including social life, productivity and health. Cannabidiol (CBD) is a constituent non …

[HTML][HTML] Endocannabinoid system as a promising therapeutic target in inflammatory bowel disease–a systematic review

S Hryhorowicz, M Kaczmarek-Ryś, A Zielińska… - Frontiers in …, 2021 - frontiersin.org
Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic
inflammatory conditions of the gastrointestinal tract of unknown etiology, including two …

Potency and therapeutic THC and CBD ratios: US cannabis markets overshoot

SD Pennypacker, K Cunnane, MC Cash… - Frontiers in …, 2022 - frontiersin.org
Background and aims: The effects exuded by cannabis are a result of the cannabinoids
trans-Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD), and is dependent upon their …

Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and …

GK Silva-Cardoso, W Lazarini-Lopes, JE Hallak… - …, 2021 - Elsevier
The incidence of chronic pain is high in the general population and it is closely related to
anxiety disorders, which promote negative effects on the quality of life. The cannabinoid …

Molecular targets of cannabidiol in experimental models of neurological disease

S Silvestro, G Schepici, P Bramanti, E Mazzon - Molecules, 2020 - mdpi.com
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid known for its beneficial effects
including antioxidant and anti-inflammatory properties. Moreover, CBD is a compound with …

[HTML][HTML] Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review

P Balachandran, M Elsohly, KP Hill - Journal of general internal medicine, 2021 - Springer
Cannabidiol, a non-intoxicating phytocannabinoid, has potential therapeutic effects over a
broad range of disorders. Recently, there has been increased interest in CBD, as several …

Endocannabinoid system and mood disorders: priming a target for new therapies

V Micale, V Di Marzo, A Sulcova, CT Wotjak… - Pharmacology & …, 2013 - Elsevier
The endocannabinoid system (ECS), comprising two G protein-coupled receptors (the
cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle∆ 9 …

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings

S Elsaid, S Kloiber, B Le Foll - Progress in molecular biology and …, 2019 - Elsevier
Cannabis sativa (cannabis) is one of the oldest plants cultivated by men. Cannabidiol (CBD)
is the major non-psychomimetic compound derived from cannabis. It has been proposed to …

ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids

S Shah, ES Schwenk, RV Sondekoppam… - Regional Anesthesia & …, 2023 - rapm.bmj.com
Background The past two decades have seen an increase in cannabis use due to both
regulatory changes and an interest in potential therapeutic effects of the substance, yet …

[HTML][HTML] Cannabidiol (CBD) is a novel inhibitor for exosome and microvesicle (EMV) release in cancer

US Kosgodage, AV Nunn, GW Guy… - Frontiers in …, 2018 - frontiersin.org
Exosomes and microvesicles (EMV) are lipid bilayer-enclosed structures, released by cells
and involved in intercellular communication through transfer of proteins and genetic …